PBYI Puma Biotechnology Inc
Legal ·
The Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB.
Puma is suing Hedrick Gardner Kincheloe & Garofalo, L.L.P. and attorney David L. Levy over its defense in the Eshelman case. The Court of Appeals revived the claim on Sept. 3, 2025.
Puma Biotechnology Inc. is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes. Its commercial product is NERLYNX, an oral version of neratinib, for certain HER2-positive breast cancers. The FDA and the European Commission have approved NERLYNX for the extended adjuvant treatment of certain patients with early stage HER2-positive breast cancer, and the FDA has approved it for certain patients with metastatic HER2-positive breast cancer. The company has in-licensed alisertib, a selective small-molecule inhibitor of Aurora Kinase A, from a subsidiary of Takeda Pharmaceutical Company Limited, and is responsible for its global development and commercialization. Puma intends to pursue alisertib initially in small cell lung cancer and hormone receptor-positive breast cancer. The text says alisertib was tested in over 1,300 patients across 22 company-sponsored trials. The company depends on international third-party sub-licensees to commercialize NERLYNX in several countries outside the United States and relies exclusively on third parties for formulation and manufacturing.
| Product or program | What it is | Stage |
|---|---|---|
| NERLYNX (neratinib) | Oral irreversible tyrosine kinase inhibitor for HER2-positive breast cancer | Approved; currently commercialized |
| Alisertib | Selective Aurora Kinase A inhibitor for small cell lung cancer and hormone receptor-positive breast cancer | Early stages of development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | $31.1 million | $30.3 million |
| Cash from operations | $41.8 million | $38.9 million |
| Cash and equivalents | $29.6 million | $69.2 million |
| Short-term investments | $67.9 million | $31.7 million |
Puma Biotechnology Inc trades under the ticker PBYI on NASDAQ.
Puma Biotechnology Inc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Puma Biotechnology Inc is 1401667. Its filings are on SEC EDGAR.
51,620,066 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Puma Biotechnology Inc under United States.
Our directory classifies Puma Biotechnology Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Puma Biotechnology Inc is US74587V1070.
aibio.space lists Puma Biotechnology Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Puma Biotechnology Inc. is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes. Its commercial product is NERLYNX, an oral version of neratinib, for certain HER2-positive breast cancers.
NERLYNX (neratinib): Oral irreversible tyrosine kinase inhibitor for HER2-positive breast cancer Stage: Approved; currently commercialized.
Alisertib: Selective Aurora Kinase A inhibitor for small cell lung cancer and hormone receptor-positive breast cancer Stage: Early stages of development.
Puma Biotechnology Inc reported net income of $31.1 million for the fiscal year ended Dec 31, 2025, and generated $41.8 million of cash from operations, per its annual report to the SEC.
$93.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Puma Biotechnology, dated Aug 6, 2026: "Federal Circuit affirms invalidity of Puma-licensed patents in Tagrisso suit against AstraZeneca". The Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio